Showing posts with label Pontine Glioma Therapeutics - Pipeline Analysis 2018. Show all posts
Showing posts with label Pontine Glioma Therapeutics - Pipeline Analysis 2018. Show all posts
Pontine Glioma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results
Pramod Kmr02:24and Other Developments, Clinical Trials & Results, Collaborations, Designations, Patents, Pontine Glioma Therapeutics - Pipeline Analysis 2018
No comments
Pontine
glioma is a malignant tumour which develops from the brain stem cells.
Based on the grade of growth, it is categorized into anaplastic astrocytomas
and glioblastoma multiforme (GBM). Pontine glioma is more prevalent in children
than adults.
The common signs and symptoms of pontine glioma are squints,
swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty
in writing and changes in personality and behaviour. The only efficient
treatment for pontine glioma is radiotherapy; as surgery is not possible due to
the tumor’s position in the brain stem.
Request to Get the Sample Pages at:
Company like Y-mAbs Therapeutics Inc. is in the process of
developing omburtamab for the treatment of pontine glioma.
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of development,
with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product
description and development activities including information about clinical
results, designations, collaborations, licensing, grants, technology, and
others.












